Novel marine compounds: Anticancer or genotoxic?

Journal of Biomedicine and Biotechnology

Volumn 2004, Issue 2, 2004, Pages 93-98

  Arif, Jamal M ^a   Al Hazzani, Amal A ^a   Kunhi, Muhammed ^a   Al Khodairy, Fahad ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; AAPTAMINE; ALPHA GALACTOSYLCERAMIDE; AZEPINE DERIVATIVE; BRYOSTATIN 1; CEMADOTIN; CRYPTOPHYCIN 52; CURCUDIOL; CURCUPHENOL; CYTARABINE; DEHYDRODIDEMNIN B; DIDEMNIN B; DISCODERMOLIDE; DOLASTATIN 10; EPOTHILONE B; GIROLLINE; ILX 651; JASPAMIDE; KAHALALIDE F; LAF 389; MANZAMINE A; MARINE TOXIN; SARCOPHINE; SQUALAMINE; TALTOBULIN; TRABECTEDIN; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERONGIAQUINOL; VIDARABINE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; BLADDER CARCINOGENESIS; BLOOD TOXICITY; BREAST CANCER; BREAST CARCINOMA; CANCER; CARCINOGENESIS; CLINICAL TRIAL; COLON CANCER; FIBROSARCOMA; GENOTOXICITY; HUMAN; HYPERTENSION; LEUKEMIA; LIVER TOXICITY; LYMPHOMA; MARINE ENVIRONMENT; MELANOMA; NONHUMAN; ONCOGENE; OVARY CANCER; PROSTATE CANCER; REVIEW; SARCOMA; SCREENING TEST; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALIA;

EID: 4644323646     PISSN: 11107243     EISSN: None     Source Type: Journal    
DOI: 10.1155/S1110724304307060     Document Type: Review

References (64)

1. Proksch P, Edrada RA, Ebel R. Drugs from the seas - current status and microbiological implications. Appl Microbiol Biotechnol. 2002;59(2-3):125-134.
2. Mayer AM, Gustafson KR. Marine pharmacology in 2000: antitumor and cytotoxic compounds. Int J Cancer. 2003;105(3):291-299.
3. Garcia-Fernandez LF, Reyes F, Sanchez-Puelles JM. The marine pharmacy: new antitumoral compounds from the sea. Pharmaceut News. 2002;9:495-501.
4. Haefner B. Drugs from the deep: marine natural products as drug candidates. Drug Discov Today. 2003;8(12):536-544.
5. Faulkner DJ. Marine pharmacology. Antonie Van Leeuwenhoek. 2000;77(2):135-145.
6. Amador ML, Jimeno J, Paz-Ares L, Cortes-Funes H, Hidalgo M. Progress in the development and acquisition of anticancer agents from marine sources. Ann Oncol. 2003;14(11):1607-1615.
7. Mayer AM, Lehmann VK. Marine pharmacology in 1999: antitumor and cytotoxic compounds. Anticancer Res. 2001;21(4A):2489-2500.
8. Schwartsmann G, Da Rocha AB, Mattei J, Lopes R. Marine-derived anticancer agents in clinical trials. Expert Opin Investig Drugs. 2003;12(8):1367-1383.
9. Mirsalis JC, Schindler-Horvat J, Hill JR, Tomaszewski JE, Donohue SJ, Tyson CA. Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance. Cancer Chemother Pharmacol. 1999;44(5):395-402.
10. Longley RE, Caddigan D, Harmody D, Gunasekera M, Gunasekera SP. Discodermolide - a new, marine-derived immunosuppressive compound. II. In vivo studies Transplantation. 1991;52(4):656-661.
11. D'Incalci M, Jimeno J. Preclinical and clinical results with the natural marine product ET-743. Expert Opin Investig Drugs. 2003;12(11):1843-1853.
12. Gomez SG, Bueren JA, Faircloth G, Albella B. Use of CFU-GM assay for prediction of human maximum tolerated dose of a new antitumoral drug: Yondelis (ET-743). Toxicol In Vitro. 2003;17(5-6):671-674.
13. Donald S, Verschoyle RD, Greaves P, et al. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Res. 2003;63(18):5902-5908.
14. Genaidy M, Kazi AA, Peyman GA, et al. Effect of squalamine on iris neovascularization in monkeys. Retina. 2002;22(6):772-778.
15. Brown AP, Morrissey RL, Faircloth GT, Levine BS. Preclinical toxicity studies of kahalalide F, a new anticancer agent: single and multiple dosing regimens in the rat. Cancer Chemother Pharmacol. 2002;50(4):333-340.
16. Wu J-H, Morris-Natschke SL, Lee K-H. Progress in the recent discovery and development of promising anticancer and anti-HIV agents from natural products in the United States. J Chinese Chem Soc. 2003;50:11-22.
17. Loganzo F, Discafani CM, Annable T, et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res. 2003;63(8):1838-1845.
18. Donia M, Hamann MT. Marine natural products and their potential applications as anti-infective agents. Lancet Infect Dis. 2003;3(6):338-348.
19. Okamura T. Effect of intrabladder instillation of various anticancer agents on carcinogenesis in rat bladder. Hinyokika Kiyo. 1988;34(11):1895-1902.
20. Hayakawa Y, Rovero S, Forni G, Smyth MJ. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci USA. 2003;100(16):9464-9469.
21. Mitsuhashi M, Wanibuchi H, Wei M, et al. No inhibition of urinary bladder carcinogenesis in rats with intravesical instillation of alpha- galactosylceramide. Asian Pac J Cancer Prev. 2003;4(1):45-50.
22. Vera MD, Joullie MM. Natural products as probes of cell biology: 20 years of didemnin research. Med Res Rev. 2002;22:102-145.
23. Rinehart KL Jr, Gloer JB, Hughes RG Jr, et al. Didemnins: antiviral and antitumor depsipeptides from a Caribbean tunicate. Science. 1981; 212(4497): 933-935.
24. Grubb DR, Wolvetang EJ, Lawen A. Didemnin B induces cell death by apoptosis: the fastest induction of apoptosis ever described. Biochem Biophys Res Commun. 1995;215(3):1130-1136.
25. Malfetano JH, Blessing JA, Homesley HD, Look KY, McGehee R. A phase II trial of didemnin B (NSC #335319) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. Am J Clin Oncol. 1996;19(2): 184-186.
26. Taylor SA, Giroux DJ, Jaeckle KA, Panella TJ, Dakhil SR, Schold SC. Phase II study of didemnin B in central nervous system tumors: a Southwest Oncology Group Study. Invest New Drugs. 1998-99;16(4):331-332.
27. Geldof AA, Mastbergen SC, Henrar RE, Faircloth GT. Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays. Cancer Chemother Pharmacol. 1999;44(4):312-318.
28. Mittelman A, Chun HG, Puccio C, Coombe N, Lansen T, Ahmed T. Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319). Invest New Drugs. 1999;17(2):179-182.
29. Kucuk O, Young ML, Habermann TM, Wolf BC, Jimeno J, Cassileth PA. Phase II trail of didemnin B in previously treated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group (ECOG) study. Am J Clin Oncol. 2000;23(3):273-277.
30. Sakai R, Rinehart KL, Kishore V, et al. Structure - activity relationships of the didemnins. J Med Chem. 1996;39(14):2819-2834.
31. Ahond A, Bedoya Zurita M, Colin M, et al. La girolline, nouvelle substance antitumorale extraite de l'eponge, Pseudaxinyssa cantharella n. sp. (Axinellidae). CR Acad Sci Paris Serie II. 1988;307:145-148.
32. Crews P, Manes LV, Boehler M. Jasplakinolide, a cyclodepsipeptide from the marine sponge, Jaspis sp. Tetrahedron Lett. 1986;27:2797-2800.
33. Smyth J, Boneterre ME, Schellens J, et al. Activity of the dolastatin analogue, LU103793, in malignant melanoma. Ann Oncol 2001;12(4):509-511.
34. Kerbrat P, Dieras V, Pavlidis N, Ravaud A, Wanders J, Fumoleau P. Phase II study of LU103793 (dolastatin analogue) in patients with metastatic breast cancer. Eur J Cancer. 2003;39(3):317-320.
35. Leary JV, Kfir R, Sims JJ, Fulbright DW. The mutagenicity of natural products from marine algae. Mutat Res. 1979;68(4):301-305.
36. Arfsten DP, Davenport R, Schaeffer DJ. Reversion of bioluminescent bacteria (Mutatox) to their luminescent state upon exposure to organic compounds, munitions, and metal salts. Biomed Environ Sci. 1994;7(2):144-149.
37. Greenwald P, Kelloff GJ, Boone CW, McDonald SS. Genetic and cellular changes in colorectal cancer: proposed targets of chemopreventive agents. Cancer Epidemiol Biomarkers Prev. 1995;4(7):691-702.
38. Arif JM, Gupta RC. Role of DNA adducts in defining bioactivation mechanism(s) of genotoxic compounds. Int J Oncol. 1996;8:681-685.
39. 32P- postlabeling assay. Carcinogenesis. 1992; 13(7):1053-1074.
40. Hemminki K. DNA adducts, mutations and cancer. Carcinogenesis. 1993;14(10):2007-2012.
41. Santella RM. DNA damage as an intermediate biomarker in intervention studies. Proc Soc Exp Biol Med. 1997;216(2):166-171.
42. Nesnow S, Ross JA, Stoner GD, Mass MJ. Mechanistic linkage between DNA adducts, mutations in oncogenes and tumorigenesis of carcinogenic environmental polycyclic aromatic hydrocarbons in strain A/J mice. Toxicology. 1995;105(2-3):403-413.
43. Arif JM, Smith WA, Gupta RC. Tissue distribution of DNA adducts in rats treated by intramammillary injection with dibenzo[a,l]pyrene, 7,12-dimethylbenz [a] anthracene and benzo[a]pyrene. Mutat Res. 1997;378(1-2):31-39.
44. Hemminki K, Koskinen M, Rajaniemi H, Zhao C. DNA adducts, mutations, and cancer 2000. Regul Toxicol Pharmacol. 2000;32(3):264-275.
45. Smith WA, Gupta RC. Use of a microsome-mediated test system to assess efficacy and mechanisms of cancer chemopreventive agents. Carcinogenesis. 1996;17(6):1285-1290.
46. Smith WA, Arif JM, Gupta RC. Effect of cancer chemopreventive agents on microsome-mediated DNA adduction of the breast carcinogen dibenzo[a,l]pyrene. Mutat Res. 1998;412(3):307-314.
47. Smith WA, Freeman JW, Gupta RC. Effect of chemopreventive agents on DNA adduction induced by the potent mammary carcinogen dibenzo[a,l]pyrene in the human breast cells MCF-7. Mutat Res. 2001;480-481:97-108.
48. Smith WA, Arif JM, Gupta RC. 1,2-dithiole-3-thione and its structural analogue oltipraz are potent inhibitors of dibenz. Int J Cancer. 2001;91(1):132-136.
49. Arif JM, Gairola CG, Glauert HP, Lubet RA, Kelloff GJ, Gupta RC. Inhibition of cigarette smoke-related lipophilic DNA adducts in rat tissues by dietary oltipraz. Carcinogenesis. 1998;19(8):1515-1517.
50. Arif JM, Gairola CG, Kelloff GJ, Lubet RA, Gupta RC. Inhibition of cigarette smoke-related DNA adducts in rat tissues by indole-3-carbinol. Mutat Res. 2000;452(1):11-18.
51. 7-guanine and serum aflatoxin-albumin adducts predicts chemoprotection by 1,2-dithiole-3-thione in rats. Carcinogenesis. 1992;13(1):101-106.
52. Egner PA, Gange SJ, Dolan PM, Groopman JD, Munoz A, Kensler TW. Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz. Carcinogenesis. 1995;16(8):1769-1773.
53. Devanaboyina U, Gairola CG, Kelloff GJ, Lubet RA, Gupta RC. Effect of indole-3-carbinol (I3C) and phenethylisothiocyanate (PEITC) on 7,12-dimethylbenz[a]anthracene (DMBA)-induced DNA adducts in rat mammary glands and liver. Proc Am Assoc Cancer Res. 1997;38:362.
54. Matsumoto SS, Sidford MH, Holden JA, Barrows LR, Copp BR. Mechanism of action studies of cytotoxic marine alkaloids: ascididemin exhibits thiol-dependent oxidative DNA cleavage. Tetrahedron Lett. 2000;41:1667-1670.
55. Aune GJ, Furuta T, Pommier Y. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action. Anticancer Drugs. 2002;13(6):545-555.
56. Pandit UK. Strategies for the synthesis of some complex antitumor alkaloids. Farmaco. 1995;50(11): 749-754.
57. Carney JR, Rinehart KL. Biosynthesis of brominated tyrosine metabolites by Aplysina fistularis. J Nat Prod. 1995;58(7):971-985.
58. Edrada RA, Proksch P, Wray V, Witte L, Muller WE, Van Soest RW. Four new bioactive manzamine-type alkaloids from the Philippine marine sponge Xestospongia ashmorica. J Nat Prod. 1996;59(11): 1056-1060.
59. El Sayed KA, Hamann MT, Waddling CA, et al. Structurally novel bioconversion products of the marine natural product sarcophine effectively inhibit JB6 cell transformation. J Org Chem. 1998; 63(21):7449-7455.
60. El Sayed KA, Kelly M, Kara UA, et al. New manzamine alkaloids with potent activity against infectious diseases. J Am Chem Soc. 2001;123(9):1804-1808.
61. El Sayed KA, Yousaf M, Hamann MT, Avery MA, Kelly M, Wipf P. Microbial and chemical transformation studies of the bioactive marine sesquiterpenes (S)-(+)-curcuphenol and -curcudiol isolated from a deep reef collection of the jamaican sponge Didiscus oxeata. J Nat Prod. 2002;65(11):1547-1553.
62. Shen YC, Lin TT, Sheu JH, Duh CY. Structures and cytotoxicity relationship of isoaaptamine and aaptamine derivatives. J Nat Prod. 1999;62(9):1264-1267.
63. D'Armas HT, Mootoo BS, Reynolds WF. An unusual sesquiterpene derivative from the Caribbean gorgonian Pseudopterogorgia rigida. J Nat Prod. 2000;63(11):1593-1595.
64. Ichiba T, Corgiat JM, Scheuer PJ, Kelly-Borges M. 8-Hydroxymanzamine A, a beta-carboline alkaloid from a sponge, Pachypellina sp. J Nat Prod. 1994;57(1):168-170.